🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the fight against superbug strains of the bacteria, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are increasing worldwide, with data suggesting over 82 million infections annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the face of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Approval

One new antibiotic, also known as Nuzolvence, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This milestone marks a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Results and Global Access

As per data released by a prominent scientific publication, the new drug cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which uses a dual-drug approach. The study included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Medical professionals directly involved have expressed positive views. The availability of a easy-to-administer therapy like this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to reduce the burden of the disease for people and to halt the transmission of untreatable gonorrhoea worldwide.